variants were found mostly as pure variants. With a median follow up of 6.5 years, patients who harbored pure variant were found at multivariablean alyses with lower survival outcomes when compared with pure urothelial carcinoma (all p<0.01). Conversely no differences were found between mixed variant vs. pure urothelial at multivariable Cox regression analyses predicting recurrence, CSM and OM (all p>0.1).
INTRODUCTION AND OBJECTIVES: Bladder cancer is the ninth most commonly diagnosed cancer worldwide, with more than 300,000 new cases per year, and it causes around 150,000 deaths every year. Despite these figures, there is scarce data in the literature on the prognosis of patients with muscle invasive bladder cancer (MIBC) who are unfit for curative treatment. Our aim is to find out the survival of patients diagnosed with MIBC who were not suitable for treatment with curative intent in our center. We also analyze variables associated with survival, as well as the number of visits to the emergency room and palliative procedures needed.
METHODS: Retrospective analysis of a cohort of patients with histopathologic diagnosis of MIBC dismissed for treatment with curative intent (cystectomy, radiotherapy and/or chemotherapy), between January 2007 and December 2012. We analyzed overall survival (OS) and cancer-specific survival (CSS), as well as their relationship with demographic (age, gender) and clinical/pathological variables (comorbidities, tumor stage, reason for dismissing curative treatment and urinary tract obstruction at diagnosis). We also evaluated the number of visits to the emergency room due to bladder cancer and palliative procedures needed: hemostatic transurethral resection (TUR), radiotherapy or nephrostomy catheter. RESULTS: We included 110 patients (96 males/14 females), with a mean age of 79. Regarding American Society of Anesthesiologists (ASA) risk, 67.3% of them were ASA III or higher; 63.6% presented with localized stage and 21.8% with metastases at diagnosis. Around half of our patients (50.9%) had urinary tract obstruction at diagnosis. The main causes to dismiss treatment with curative intent were comorbidities (39.1%) and advanced stage (36.4%). OS at 1 and 2 years was 30% and 14% respectively, with a median OS of 7.17 months. CSS at 1 and 2 years was 50% and 28% respectively, with a median CSS of 12.1 months. Variables associated with a worse survival were advanced clinical stage and urinary tract obstruction. Patients attended the emergency room a mean of 2.85 times due to their cancer. In our series, 18.2% of the patients underwent hemostatic TUR, whilst 10% needed hemostatic radiotherapy and nephrostomy catheters were placed in 24.5% of them.
CONCLUSIONS: In our series we find out an OS under 2 years in most of the patients, with a median OS under 1 year. Factors associated with worse prognosis were the presence of urinary tract obstruction at diagnosis and advanced clinical stage.
Source of Funding: None. DO PATIENTS WITH MUSCLE-INVASIVE BLADDER  CANCER UNDERGOING BLADDER-PRESERVING  RADIOTHERAPY/CHEMORADIOTHERAPY AT ACADEMIC  CENTERS HAVE IMPROVED SURVIVAL OUTCOMES  COMPARED TO THOSE TREATED AT NON-ACADEMIC  CENTERS? Amishi Bajaj*, Robert Blackwell, Brendan Martin, Alec Block, Mark Korpics, Ellen Gaynor, Elizabeth Henry, Matthew Harkenrider, Gopal Gupta, Abhishek Solanki, Maywood, IL INTRODUCTION AND OBJECTIVES: Bladder-preserving therapy with transurethral resection of bladder tumor followed by radiotherapy (RT), preferably with concurrent chemotherapy (CRT) is an alternative to Radical Cystectomy (RC) in select patients. Studies suggest improved outcomes with RC at academic centers (ACs) compared to non-academic centers (NACs). There are no data describing the impact of facility type on RT-based treatment. Yet, given the multidisciplinary care needed to execute high-quality multimodality bladder-preserving approaches, some argue that the excellent outcomes seen in bladder-preservation trials can only be reproduced at select centers of excellence, typically AC. We analyzed the National Cancer Database to determine if treatment at an AC is associated with improved overall survival (OS) for patients undergoing RT or CRT for muscle-invasive bladder cancer (MIBC).
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METHODS: Patients diagnosed with cT2-4 N0-3 M0 transitional cell MIBC from 2008 to 2012 and treated with RT or CRT were selected. Facility type was dichotomized into AC and NAC. The Kaplan-Meier method was used for OS. Univariate analysis (UVA) for OS was performed using the Log-Rank test for all clinical, demographic, and treatment-related covariates. Multivariable analysis (MVA) using the Cox proportional hazards model was used to assess the association of facility type with OS while controlling for facility case volume and all other covariates with p-value <0.1 on UVA.
RESULTS: 872 patients at 452 unique facilities were selected. 502 (58%) patients received RT, and 370 (42%) patients received CRT. 237 (27%) were treated at an AC, and 635 (73%) were treated at a NAC. 2-year OS was 61% and 53%, for patients receiving 60 Gy or greater at ACs and NACs, respectively. On UVA, facility type was not associated with OS (p¼.11). MVA, controlling for facility case volume, age, sex, education, T Stage, N Stage, RT dose, Charlson-Deyo comorbidity score, census region, and population density, demonstrated that although there was a trend, treatment at an AC was not associated with improved OS (Hazard Ratio .86, 95% Confidence Interval .71-1.04; p¼.06).
CONCLUSIONS: Similar survival outcomes are seen in patients with MIBC treated with RT and CRT at ACs and NACs. Thus, these approaches can confidently be offered at all centers with multidisciplinary collaboration and clinician experience, and bladder-preserving therapy should be discussed with patients as a valid option when counseling them prior to treatment. 197, No. 4S, Supplement, Sunday, May 14, 2017 
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